1
|
Verdin V, Mattart L, Cusumano PG, De Hertogh O, De Meester C, Francart D, Kirova YM, Nelissen X, Sacino F, Vanderick J, Weerts J, Markiewicz S. Angiosarcoma associated with radiation therapy after treatment of breast cancer. Retrospective study on ten years. Cancer Radiother 2021; 25:114-118. [PMID: 33487559 DOI: 10.1016/j.canrad.2020.05.020] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Revised: 05/29/2020] [Accepted: 05/29/2020] [Indexed: 10/22/2022]
Abstract
PURPOSE The breast sarcoma induced by radiation therapy is rare but increasing, given the increased long-term survival of patients receiving radiation therapy. Fibrosarcoma, histiocytofibroma and angiosarcoma are the most common breast sarcoma. Angiosarcoma is the most common after breast cancer treated by radiation therapy, often diagnosed too late, with a severe prognosis and a high rate of recurrence. However, because of the low incidence of angiosarcoma associated with radiation therapy (AAR), the benefit of radiation therapy in breast cancer treatment outweighs the risk to develop angiosarcoma. The aim of this study is to evaluate these rare cases of AAR diagnosed in eastern Belgium in comparison to the data from the literature. PATIENTS AND METHODS Nine cases of AAR after radiation for breast ductal carcinoma were included in this retrospective study. AAR was diagnosed according to Cahan criteria between January 2007 and December 2016. Latency, incidence, management and prognosis are comparable to the literature. RESULTS, CONCLUSION The median latency was 10 (4-24) years, the incidence of AAR in the East Belgian area was 0.09% of the patients irradiated on the same period. Patients were treated by surgery with wide local excision with or without reconstructive surgery, without radiotherapy and chemotherapy treatment. Kaplan-Meier analysis showed median overall survival of 61.8 months, patient survival of 55.6% at one year and 29.6% at five years. With the constant progress of medicine and its technologies, it would be possible to limit the occurrence of AAR or to diagnose it at an earlier stage.
Collapse
Affiliation(s)
- V Verdin
- Department of Abdominal Surgery, CHC Groupe Santé, boulevard Patience et Beaujonc, 2, 4000 Liège, Belgium.
| | - L Mattart
- Department of Abdominal Surgery, CHC Groupe Santé, boulevard Patience et Beaujonc, 2, 4000 Liège, Belgium.
| | - P G Cusumano
- Department of Obstetric Gynaecology, CHC Groupe Santé, boulevard Patience et Beaujonc, 2, 4000 Liège, Belgium.
| | - O De Hertogh
- Department of Radiation Oncology, Verviers Regional Hospital Center, Rue du Parc, 29, 4800 Verviers, Belgium.
| | - C De Meester
- Department of Abdominal Surgery, CHC Groupe Santé, boulevard Patience et Beaujonc, 2, 4000 Liège, Belgium.
| | - D Francart
- Department of Abdominal Surgery, CHC Groupe Santé, boulevard Patience et Beaujonc, 2, 4000 Liège, Belgium.
| | - Y M Kirova
- Department of Radiation Oncology, Institut Curie, Rue d'Ulm, 26, 75005 Paris, France.
| | - X Nelissen
- Department of Plastic and Reconstructive Surgery, CHC Groupe Santé, boulevard Patience et Beaujonc, 2, 4000 Liège, Belgium.
| | - F Sacino
- Department of Radiation Oncology, University of Liège, Avenue de l'Hôpital, 1, 4000 Liège, Belgium.
| | - J Vanderick
- Department of Radiation Oncology, University of Liège, Avenue de l'Hôpital, 1, 4000 Liège, Belgium.
| | - J Weerts
- Department of Abdominal Surgery, CHC Groupe Santé, boulevard Patience et Beaujonc, 2, 4000 Liège, Belgium.
| | - S Markiewicz
- Department of Abdominal Surgery, CHC Groupe Santé, boulevard Patience et Beaujonc, 2, 4000 Liège, Belgium.
| |
Collapse
|